Interferon free regimens for the “difficult to treat”: are we there?
Maria-Carlota Londoño, Sabela Lens, Xavier Forns PII: S0168-8278(13)00021-4
Reference: JHEPAT 4556 To appear in: Journal of Hepatology
Received Date: 11 December 2012 Revised Date: 7 January 2013 Accepted Date: 8 January 2013
(In Press Accepted Manuscript)
This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.
Developments in the treatment of chronic hepatitis C over the last 2 years have been remarkable. For the first time ever, we are now certain that this chronic infection can be cured without the need of interferon and ribavirin. Gane and colleagues provided the proof of concept that oral antiviral therapy with two direct-acting antivirals (DAAs) without interferon can suppress viral replication (1). In their study, they showed that the combination of a NS5B nucleoside polymerase inhibitor (RG7128) and a NS3 protease inhibitor (danoprevir) had potent antiviral activity even in null-responders; some patients achieved undetectable HCV-RNA only 14 days after treatment initiation. Unfortunately, the combination of DAAs in this study was limited to 2 weeks and was followed immediately by treatment with peginterferon and ribavirin, thus preventing the assessment of sustained virological response to an interferon-free regimen (1). The combination of the protease inhibitor asunaprevir with the NS5A inhibitor daclatasvir is the first oral interferon-free regimen proved to be effective (2, 3). In the study by Lok et al (2), 11 previous null responders received both drugs for 24 weeks and a total of 4 patients (2 of 9 with HCV genotype 1a and 2 of 2 with genotype 1b) achieved a sustained virologic response (SVR).
In the study by Chayama et al (3) 11 genotype 1b null responders underwent the same interferon-free regimen and the 9 individuals who completed 24 weeks of therapy achieved SVR. In this issue of Journal of Hepatology, Suzuki et al (4) evaluated the efficacy of dual therapy with asunaprevir and daclatasvir in 43 subjects infected with genotype 1b considered poor candidates for current treatment for hepatitis C (21 null-responders and 22 ineligible or intolerant to interferon-based therapy). SVR at 12 and 24 weeks was 90% for null-responders and 64% for ineligible/intolerant to interferon-based therapies.
Treatment was well tolerated and virological failures were only observed in the cohort of ineligible/intolerant patients (3 breakthroughs and 4 relapses). In the accompanying manuscript, Karino et al (5) characterized the escape viral mutations in patients experiencing virological failures. The authors found that NS3 and NS5 resistance-associated variants (RAVs) were detected together at the time of virological failures.
One of the strengths of the study of Suzuki et al (4) is that it deals with difficult to treat patients: well documented null responders and patients who are intolerant or ineligible to interferon. Although the latter group was rather heterogeneous (individuals older than 70 years, with depression or other comorbidities), this profile of patients represents a significant proportion of our current candidates to antiviral therapy. Obviously, the combination of peginterferon, ribavirin and a first generation protease inhibitor (boceprevir or telaprevir) is not an option for patients with absolute contraindications to interferon and it is also a poor choice for individuals with comorbidities or those who are old. In Japan and China, hepatitis C virus expanded decades before that of the United States and Europe (6). Therefore, candidates to antiviral therapy in Asia are often older than corresponding patients in Western countries. Older age is not an absolute contraindication for an interferon-based therapy. A French group showed good efficacy in a small group of patients older than 65 years treated with pegylated interferon and rivabirin (7). Nevertheless, other studies have demonstrated a trend towards lower SVR rates, as well as higher rates of dose reductions and discontinuations of therapy in this population as compared to younger individuals (6, 8). Currently, there are no data on the safety and efficacy of triple therapy in old patients. In the CUPIC French cohort, cirrhotic patients up to 83 years old have been included: though the number of severe adverse events using triple therapy seems clearly higher than those reported with peginterferon and ribavirin alone (9), a specific analysis in older patients has not been performed.
Similarly, triple therapy is not an ideal alternative for most previous null responders, since SVR rates in this subpopulation ranks only between 30% to 40% (10, 11). Moreover, subgroup analyses from the REALIZE study (10) suggests that in cirrhotic null responders SVR is below 15%. In order to accomplish the definition of “difficult to treat” patients it would have been interesting if the study by Suzuki et al. had included patients with advanced liver disease (biopsy-proven cirrhosis was an exclusion criteria).
Response rates obtained in this study using daclatasvir and asunaprevir can be considered excellent. It is surprising though, that the only the virological failures reported were in the group of intolerant/ineligible patients (5). Although the small number of patients precludes any definitive interpretation, there are several potential explanations. Firstly, it is important to notice that 10 out of the 21 null responders (sentinel cohort) received a significantly higher dose of asunaprevir, which was not the case in any of the 22 intolerant/ineligible individuals. Second, patients experiencing virological failure had below-median daclatasvir and asunarpevir levels, but this was also the case for other individuals who achieved sustained viral clearance. A lack of compliance did not seem to play a major role in the lower efficacy in this group (though cannot be completely excluded). A more interesting hypothesis is the potential effect of pre-existing resistance-associated variants (RAVs). In a complementary manuscript Karino et al. (5) performed a careful characterization of virological escape mutants in patients included in the first study. Interestingly, most patients experiencing viral breakthrough or relapse had daclatasvir RAVs at baseline, being NS5A-Y93H the predominant polymorphism in all 3 patients with virological breakthrough and in 2 of the 4 relapsers. The global prevalence of this variant is around 4% (5, 12) and may be higher in genotype 1b-infected patients (~ 10%). Indeed, NS5A-Y93H was found at baseline in five other patients who achieved SVR in this study.
In every patient with virological failure resistant variants to both agents emerged together at the time of failure (NS3-D168A/V and NS5A-L31M/V-Y93H). At baseline, a combination of these NS3 and NS5A variants was not detected by clonal sequencing; however their presence at low levels cannot be excluded due to the limited number of clones analyzed. Currently, assessment of minor NS3 plus NS5A RAVs from the same RNA sequence is not possible by ultradeep sequencing technologies, since the size of the analyzed fragments is still a limitation (a fragment of ~ 4000 base pairs encompassing NS3, NS4 and NS5A is fair too large for the current technology).
A final point analyzed in the accompanying manuscript by Karino et al was the persistence of RAVs after treatment interruption (5). This is a very relevant topic, since it may impact future treatment options in patients who develop drug resistance. As reported with other protease inhibitors, asunaprevir-resistant NS3-D168 substitutions generally decayed during the follow-up period, which implies a lack of replicative fitness compared to the wild-type virus in the absence of selective pressure (drug). This was also reproduced in the replicon system, where double NS3 RAVs (D168V plus Q80L or S122G) had a replicative ability similar to the D168V variant alone. Obviously, a more thorough sequence analysis using ultra-deep pyrosequencing would be necessary to fully establish the dynamic decay of these RAVs after treatment interruption and to make sure that these variants do not remain enriched for longer periods relative to baseline. In fact, a small study including 5 patients who were first treated with simeprevir monotherapy (5 days) and then retreated more than 1 year later with pegylated interferon, ribavirin and simepervir analyzed the potential clinical implications of the presence of RAVs. In this study (13) 3 patients achieved SVR and 2 did not. Deep sequencing indicated low-level persistence of simeprevir RAVs in the 2 patients who did not achieve SVR. We do not know if the presence of these resistant strains at low levels explained the lack of response to re-treatment. What is really interesting in the study by Karino et al (5) is that in some individuals, NS5A variants associated with daclatavir resistance persisted for at least 48 weeks after treatment interruption. As already mentioned, longer follow-up studies are important to establish the clinical impact of these more fitted resistant strains in case these patients will be retreated with NS5A inhibitors.
Overall, the ideal combination of DAAs is still unknown, but some of the inherent characteristics of the antiviral agents may help to predict which combination will be more effective (Table 1). The inclusion of a nucleo(s)tide NS5B polymerase inhibitor in a combination seems reasonable (14). These drugs offer a high barrier to resistance (RAVs have a very poor fitness), are pangenotypic and have proved to be very effective in several phase 2 trials. The simple combination of sofosbuvir and ribavirin for 12 weeks appears to be extremely successful in naïve genotype 1, 2 or 3 patients (though this combination using such a short regimen is insufficient to cure previous null responders) (15). Combinations including more than 2 DAAs targeting different viral proteins also seem a good approach. Recently, a study including both naïve and null responder genotype 1 patients assessed the efficacy of ABT450/r (ritonavir-boosted NS3 inhibitor), ABT267 (NS5B non nucleoside inhibitor), ABT 333 (NS5A inhibitor) and ribavirin. This combination SVR12 rates close to 100% in naives and around 90% in null-responders (16). Unfortunately, patients with advanced liver disease have not yet been included in these studies. The only data regarding cirrhotic patients treated with oral regimens comes from the SOUND-C2 study, where a NS3 protease inhibitor (faldaprevir), a non nucleoside NS5B inhibitor (BI207127) and ribavirin were combined in genotype 1 naïve patients: reported SVR12 rates in cirrhotics were around 60%(17).
Within the next few years, we will certainly witness more progress. When choosing a combination of antiviral agents, we will need to take into consideration a certain number of variables: potency, genetic barrier to resistance, range of activity (pangenotypic or not), potential drug-drug interactions. Importantly, safety and simplicity of the regimen will also be very relevant. Up to now, most of the oral compounds appear to be safe and well tolerated by most patients, but until large phase 3 studies are finished, safety needs to be closely monitored. Most of our current knowledge on interferon-free regimes is based on phase 2 trials including small numbers of patients. Added to which, we still have very little information on the safety and efficacy of these regimens in difficult to treat subjects, particularly in null responders with advanced fibrosis or cirrhosis, or in special populations such as transplant patients with hepatitis C recurrence. Over the next 2 to 3 years, we will start to see data on large cohorts (phase 3 studies) and in small series of really difficult to treat individuals and in special populations. By then, it will be easier to answer the question: are we there?
Table 1. Characteristics of direct antiviral agents approved for hepatitis C treatment or entering phase 3 studies.
1. Gane EJ, Roberts SK, Stedman CA, Angus PW, Ritchie B, Elston R, Ipe D, et al. Oral combination therapy with a nucleoside polymerase inhibitor (RG7128) and danoprevir for chronic hepatitis C genotype 1 infection (INFORM-
1): a randomised, double-blind, placebo-controlled, dose-escalation trial. Lancet
2. Chayama K, Takahashi S, Toyota J, Karino Y, Ikeda K, Ishikawa H,Watanabe H, et al. Dual therapy with the nonstructural protein 5A inhibitor,daclatasvir, and the nonstructural protein 3 protease inhibitor, asunaprevir, in hepatitis C virus genotype 1b-infected null responders. Hepatology
3. Lok AS, Gardiner DF, Lawitz E, Martorell C, Everson GT, Ghalib R,Reindollar R, et al. Preliminary study of two antiviral agents for hepatitis C genotype 1. N Engl J Med 2012;366:216-224.
4. Suzuki Y, Ikeda K, Suzuki F, Toyota J, Karino Y, Chayama K, Kawakami Y, et al. Dual Oral Therapy with Daclatasvir and Asunaprevir for Patients with HCV Genotype 1b Infection and Limited Treatment Options. J Hepatol 2012.
5. Karino Y, Toyota J, Ikeda K, Suzuki F, Chayama K, Kawakami Y, Ishikawa H, et al. Characterization of virologic escape in hepatitis C virus genotype 1b patients treated with the direct-acting antivirals daclatasvir and asunaprevir. J Hepatol 2012.
6. Iwasaki Y, Ikeda H, Araki Y, Osawa T, Kita K, Ando M, Shimoe T, et al. Limitation of combination therapy of interferon and ribavirin for older patients with chronic hepatitis C. Hepatology 2006;43:54-63.
7. Thabut D, Le Calvez S, Thibault V, Massard J, Munteanu M, Di Martino V, Ratziu V, et al. Hepatitis C in 6,865 patients 65 yr or older: a severe and neglected curable disease? Am J Gastroenterol 2006;101:1260-1267.
8. Hu CC, Lin CL, Kuo YL, Chien CH, Chen SW, Yen CL, Lin CY, et al. Efficacy and safety of ribavirin plus pegylated interferon alfa in geriatric patients with chronic hepatitis C. Aliment Pharmacol Ther 2013;37:81-90.
9. Hezode C, Dorival C, Zoulim F, Larrey D, Pol S, Cacoub P, Canva V, et al. Safety and efficacy of telaprevir or boceprevir in combination with peginterferon alfa/ribavirin, in 455 cirrhotic non responders. Week 16 analysis of the French early access program (ANRS CO20-CUPIC) in real-life setting. (Abstract). Hepatology 2012;56:217A.
10. Zeuzem S, Andreone P, Pol S, Lawitz E, Diago M, Roberts S, Focaccia R, et al. Telaprevir for retreatment of HCV infection. N Engl J Med 2011;364:2417-2428.
11. Vierling JM, Flamm SL, Gordon S, Lawitz E, Bronowicki JP, Davis M, Yoshida EM, et al. Efficacy of Boceprevir en prior null-responders to Peginterferon and Ribavirin: The PROVIDE Study. (Abstract). Hepatology 2011;54:796A.
12. Kuiken C, Yusim K, Boykin L, Richardson R. The Los Alamos hepatitis C sequence database. Bioinformatics 2005;21:379-384.
13. Lenz O, de Bruijne J, Vijgen L, Verbinnen T, Weegink C, Van Marck H, Vandenbroucke I, et al. Efficacy of Re-treatment With TMC435 as Combination Therapy in Hepatitis C Virus-Infected Patients Following TMC435 Monotherapy. Gastroenterology 2012;143:1176-1178 e1176.
14. Chung RT. A watershed moment in the treatment of hepatitis C. N Engl J Med 2012;366:273-275.
15. Gane EJ, Stedman CA, Hayland RH, Sorensen RD, Symonds WT, Hindes R, Berrey MM. Once Daily Sofosbuvir (GS-7977) Plus Ribavirin in Patients with HCV Genotypes 1, 2, and 3: The ELECTRON Trial. Hepatology 2012;56:306A.
16. Kowdley K, Lawitz E, Poordad F, Cohen DE, Nelson DR, Zeuzem S, Everson GT, et al. A 12-Week Interferon-free Treatment Regimen with ABT- 450/r, ABT-267, ABT-333 and Ribavirin Achieves SVR12 Rates (Observed Data) of 99% in Treatment-Naïve Patients and 93% in Prior Null Responders with HCV Genotype1 Infection. (LB Abstract). AASLD 2012.
17. Soriano V, Gane EJ, Angus P, Stickel F, Bronowicki JP, Roberts S, Manns MP, et al. Efficacy and safety of the interferon (IFN)-free combination of BI 201335 + BI 207127 ± ribavirin (RBV) in treatment-naïve patients with HCV genotype (GT) 1 infection and compensated liver cirrhosis: Results from the SOUND-C2 study (Abstract). Hepatology 2012;56:234A.